Pfizer
About the company
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Price above modeled range
Other models: USD 10.37–16.32 (median 13.34). The recommended value is 55% above that median, so treat the upside with extra caution.
Why: Dividends are a large share of earnings, so the cash paid to shareholders is the best guide to value.
The range depends on model assumptions and data; it is not a prediction or investment advice.
After signing in, return here and select “Add to watchlist”. Saving companies requires a verified email address.
Market price above modeled range
Uses reported dividends of USD 1.7200 per share from Fiscal year 2025, with 2% perpetual growth (base growth capped at the terminal rate) and 10.5% discount rates. The range varies growth and discount assumptions by 1 percentage point; it is illustrative, not a statistical confidence interval or investment advice.
Assumptions: growth 2%, discount rate 10.50%, terminal growth 2.90% (sector defaults). See a worked example.
Blended growth assumption: 2.0% (sector default 6.8%, own revenue history -6.3%, analyst revenue consensus -3.8%).
5-year outlook: relative outlook of about 5.5% a year (High confidence), anchored to a 7% market return and adjusted for how this company ranks against others. A ranking aid, not a prediction. See the full forecast.
Analyst consensus expects revenue growth of -3.8% a year; the growth assumption used is 2.0%.
Adjust assumptions
Why this model: Dividends are a large share of earnings, so the cash paid to shareholders is the best guide to value.
Compare models- Recommended: Dividend discount model — USD 20.64 (-29.8%)
-
EPS-based Gordon proxy
— USD 16.32 (-44.5%)
Not used: Treats all earnings as if paid out and ignores the cash kept for reinvestment, so it overstates value for companies that retain most profit.
-
DCF (trailing free cash flow)
— USD 9.56 (-67.5%)
Not used: Not chosen: Dividend discount model ranks ahead of it for this company.
-
FCFF (steady state)
— USD 10.37 (-64.7%)
Not used: Assumes only the long-run terminal growth rate from today, so it ignores the near-term growth expected.
-
EV/EBITDA (12x)
— not applicable
Not used: Cannot be computed: EBITDA is missing, zero or negative.
-
Fade DCF (10-year growth fade)
— USD 9.59 (-67.4%)
Not used: An alternative growth path (fading over 10 years) shown for comparison; the automatic choice does not use it.
-
EV/Sales (Rule of 40)
— not applicable
Not used: Cannot be computed: revenue is missing.
| Bear USD 16.54 | -77.6% |
| Base USD 20.64 | -42.4% |
| Bull USD 27.26 | -7.8% |
Margin = (value − price) / value, so it is measured against the value and reads lower than the upside to value, which is measured against the price. Positive means the price is below that case.
At USD 29.39 the market implies perpetual dividend growth of about this rate (discount rate 10.5%).
Compare: the market implies 4.4% a year, this model assumes 2.0%. The market expects more than this model does, which is why it reads as overvalued.
Sensitivity: base value per share
How the Dividend discount model value changes with growth (rows) and discount rate (columns). Green cells are above the current price. Dividend growth cannot exceed the long-run rate, so duplicate capped scenarios are omitted.
These are assumption-based scenarios, not a confidence interval. Scroll horizontally to see all discount rates.
| Growth \ Discount | 8.5% | 9.5% | 10.5% | 11.5% | 12.5% |
|---|---|---|---|---|---|
| -2.0% | 16.05 | 14.66 | 13.48 | 12.49 | 11.62 |
| 0.0% | 20.24 | 18.11 | 16.38 | 14.96 | 13.76 |
| 2.0% | 26.99 | 23.39 | 20.64 | 18.47 | 16.71 |
| 2.9% | 31.60 | 26.82 | 23.29 | 20.58 | 18.44 |
Track record: see the methodology page for how this model has performed historically, including its limits. Treat it as a screen, not a forecast.
Price history and fair value
5 years price change: -20.15% · USD 29.45 · Market data through 05 Nov 2026 ; dashed line is today’s model base value (USD 20.64). The fair value is today’s estimate, not what the model said in the past.
Saved price history is current through 05 Nov 2026; last refreshed 06 Nov 2026 18:33 (8 hours, 13 minutes ago).
08 Nov 2021Range USD 19.40 – 45.3905 Nov 2026
Latest news
Headlines provided by EODHD. Articles may mention multiple companies and are not investment recommendations.
More detail: quality, peers, price history, dividends and financials
Quality score: 73 / 100
Five equal checks on reported history: profitability, cash generation, revenue growth, balance sheet and margins. It describes business quality, not whether the price is attractive.
| Profitability | 5 of 5 years profitable | 20 / 20 |
| Cash generation | free cash flow positive in 5 of 5 years | 20 / 20 |
| Growth | revenue -10.9% a year | 4 / 20 |
Peers in Health Care
Same-sector companies with a valuation, most undervalued first. Compare the margin of safety, yield and quality score side by side.
| Company | Price | Margin of safety | P/E | P/B | Yield | Quality |
|---|---|---|---|---|---|---|
| PFE (this company) | USD 29.39 | -42.4% | 41.5 | 1.9 | 5.9% | 73 |
| CNC Centene Corporation | USD 69.74 | 45.1% | 23.6 | 1.6 | – | 72 |
| ZEAL.CO Zealand Pharma A/S | DKK 232.90 | 36.5% | 6.0 | 0.9 | – | 72 |
| CI Cigna | USD 293.59 | 30.6% | 12.1 | 1.8 | 2.1% | 70 |
| BAVA.CO Bavarian Nordic A/S | DKK 241.00 | 12.0% | 11.9 | 1.4 | – | 92 |
| CVS CVS Health | USD 83.85 | 9.7% | 9.8 | 1.3 | 3.2% | 70 |
| AMP.MI Amplifon S.p.A. | EUR 11.17 | 8.7% | 41.1 | – | 2.6% | 72 |
| ZBH Zimmer Biomet | USD 105.59 | 1.6% | 26.3 | 1.6 | 0.9% | 90 |
| GSK.L GSK plc | GBP 18.90 | -5.4% | 17.7 | 4.1 | 3.5% | 92 |
| Peer median | 14.9 | 1.6 | ||||
Dividends
Paid in the last 12 months: USD 1.72 per share · yield 5.85% at the current price.
| Year | Dividends per share |
|---|---|
| 2026 (so far) | 1.720 |
| 2025 | 1.720 |
| 2024 | 1.680 |
| 2023 | 1.640 |
| 2022 | 1.600 |
| 2021 | 1.560 |
Annual financial statement
Saved annual report · Fiscal year 2025 · SEC EDGAR annual filings · period ended 31 Dec 2025
| Revenue | USD 62,579,000,000 |
|---|---|
| EBITDA | USD |
| EBIT | USD |
| Net income | USD 7,771,000,000 |
| Free cash flow | USD 9,075,000,000 |
| Capital expenditures | USD -2,629,000,000 |
| Debt | USD 64,795,000,000 |
| Cash | USD 1,142,000,000 |
| Working capital | USD 5,914,000,000 |
| Shares outstanding | 5,713,000,000 |
| Reported dividends per share | USD 1.7200 |